These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 38594129)

  • 1. SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes.
    Hochman MJ; DeZern AE
    Clin Lymphoma Myeloma Leuk; 2024 Sep; 24(9):573-582. PubMed ID: 38594129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2023 Aug; 98(8):1307-1325. PubMed ID: 37288607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2014 Jan; 89(1):97-108. PubMed ID: 24464505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2012 Jul; 87(7):692-701. PubMed ID: 22696212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
    Montalban-Bravo G; Garcia-Manero G
    Am J Hematol; 2018 Jan; 93(1):129-147. PubMed ID: 29214694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
    Sekeres MA; Taylor J
    JAMA; 2022 Sep; 328(9):872-880. PubMed ID: 36066514
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Ball S; Loghavi S; Zeidan AM
    Leuk Lymphoma; 2023 Mar; 64(3):540-550. PubMed ID: 36323304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Approaches to Myelodysplastic Syndrome Treatment.
    Bazinet A; Bravo GM
    Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2011 Jun; 86(6):490-8. PubMed ID: 21594886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
    Garcia-Manero G; Chien KS; Montalban-Bravo G
    Am J Hematol; 2020 Nov; 95(11):1399-1420. PubMed ID: 32744763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress.
    Venugopal S; Shallis RM; Zeidan AM
    Expert Rev Anticancer Ther; 2023; 23(9):903-911. PubMed ID: 37470508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
    Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the management of higher-risk myelodysplastic syndromes: future prospects.
    Gener-Ricos G; Rodriguez-Sevilla JJ; Urrutia S; Bataller A; Bazinet A; Garcia-Manero G
    Leuk Lymphoma; 2024 Sep; 65(9):1233-1244. PubMed ID: 38712556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS).
    Lucero J; Al-Harbi S; Yee KWL
    Curr Oncol; 2023 Jun; 30(7):6177-6196. PubMed ID: 37504319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic approaches for the management of higher risk myelodysplastic syndromes.
    Wang C; Sallman DA
    Leuk Lymphoma; 2023 Mar; 64(3):511-524. PubMed ID: 36433645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SOHO State of the Art and Next Questions: Treatment of Higher-Risk Myelodysplastic Syndromes.
    Aubrey BJ; Brunner AM
    Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):869-877. PubMed ID: 36030175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
    Dodillet H; Kreuzer KA; Monsef I; Skoetz N
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
    Stahl M; Zeidan AM
    Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
    Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.